Drugs / MenACYW
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02955797 | Feb → Oct 2017 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenACYW | “The purpose of the study was to evaluate the immunogenicity and describe the safety of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid...” NCT02955797 ↗ |
| Modality | Vaccine | “MenACYW Conjugate vaccine” NCT02955797 ↗ |
| Route | Intramuscular | “0.5 milliliter (mL), Intramuscular” NCT02955797 ↗ |